Farah Ghamloush

Beirut, BA, Lebanon

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Clinical Research Capacity Building in Pediatric Oncology in Resource-Limited Settings: Application and Early Results of Regional Educational Workshops.

Clinical Research Capacity Building in Pediatric Oncology in Resource-Limited Settings: Application and Early Results of Regional Educational Workshops.

Journal: JCO global oncology

Published: July 29, 2026

Navigating the Planning and Initiation of a First Prospective Clinical Trial Through a Regional Pediatric Oncology Consortium Within the Middle East, Africa, and Asia-A Roadmap.

Navigating the Planning and Initiation of a First Prospective Clinical Trial Through a Regional Pediatric Oncology Consortium Within the Middle East, Africa, and Asia-A Roadmap.

Journal: Pediatric blood & cancer

Published: April 15, 2026

Highlights From the 2025 Pediatric Oncology East and Mediterranean Biennial Conference: Advancing Pediatric Oncology Across the Eastern Mediterranean.

Highlights From the 2025 Pediatric Oncology East and Mediterranean Biennial Conference: Advancing Pediatric Oncology Across the Eastern Mediterranean.

Journal: JCO global oncology

Published: January 23, 2026

Exosome-Mediated Paracrine Signaling Unveils miR-1246 as a Driver of Aggressiveness in Fusion-Negative Rhabdomyosarcoma.

Exosome-Mediated Paracrine Signaling Unveils miR-1246 as a Driver of Aggressiveness in Fusion-Negative Rhabdomyosarcoma.

Journal: Cancers

Published: February 16, 2024

CD147 Promotes Tumorigenesis via Exosome-Mediated Signaling in Rhabdomyosarcoma.

CD147 Promotes Tumorigenesis via Exosome-Mediated Signaling in Rhabdomyosarcoma.

Journal: Cells

Published: May 25, 2022

Effects of the Oncoprotein PAX3-FOXO1 on Modulation of Exosomes Function and Protein Content: Implications on Oxidative Stress Protection and Enhanced Plasticity.

Effects of the Oncoprotein PAX3-FOXO1 on Modulation of Exosomes Function and Protein Content: Implications on Oxidative Stress Protection and Enhanced Plasticity.

Journal: Frontiers in oncology

Published: February 15, 2020

The PAX3-FOXO1 oncogene alters exosome miRNA content and leads to paracrine effects mediated by exosomal miR-486.

The PAX3-FOXO1 oncogene alters exosome miRNA content and leads to paracrine effects mediated by exosomal miR-486.

Journal: Scientific reports

Published: June 18, 2019

The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma.

The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma.

Journal: Cancer biology & therapy

Published: October 12, 2018

Exosomes derived from embryonal and alveolar rhabdomyosarcoma carry differential miRNA cargo and promote invasion of recipient fibroblasts.

Exosomes derived from embryonal and alveolar rhabdomyosarcoma carry differential miRNA cargo and promote invasion of recipient fibroblasts.

Journal: Scientific reports

Published: June 09, 2016

The synthetic retinoid ST1926 as a novel therapeutic agent in rhabdomyosarcoma.

The synthetic retinoid ST1926 as a novel therapeutic agent in rhabdomyosarcoma.

Journal: International journal of cancer

Published: July 31, 2015

p53 Restoration in Induction and Maintenance of Senescence: Differential Effects in Premalignant and Malignant Tumor Cells.

p53 Restoration in Induction and Maintenance of Senescence: Differential Effects in Premalignant and Malignant Tumor Cells.

Journal: Molecular and cellular biology

Published: July 30, 2015

CDK2 transcriptional repression is an essential effector in p53-dependent cellular senescence-implications for therapeutic intervention.

CDK2 transcriptional repression is an essential effector in p53-dependent cellular senescence-implications for therapeutic intervention.

Journal: Molecular cancer research : MCR

Published: August 24, 2014

Showing 1-12 of 12

Last Updated: 09/26/2026